Parkinson’s Disease - Early Differential Diagnosis of Parkinsonism with Metabolic Imaging and Pattern Analysis
Protocol ID
Protocol Description
Parkinson’s disease (PD) is the most common cause of symptoms of rigidity, resting tremor, and bradykinesia (slowness of movement). However, other conditions such as multisystem atrophy (MSA) and progressive supranuclear palsy (PSP) can produce very similar clinical signs, especially in their early stages. Because these conditions all begin with the same type of symptoms, some patients have been misdiagnosed with PD but actually suffer from a different disease. This poses problems for both patient care and clinical trials. This research study will test a new automated image-based categorization algorithm (or a problem-solving computer program) to provide accurate diagnosis of PD within two years of the onset of patient symptoms (or perhaps even before symptoms appear in at-risk patients with idiopathic Rapid Eye Movement Behavior Disorder (RBD). We hope that this research project will ultimately help researchers recruit true PD (or MSA or PSP) patients to track disease progression in clinical trials. Accurate early diagnosis would also help optimize patient care through proper treatment.
We will measure brain function with imaging methods (Positron Emission Tomography – PET scanning), neurological examinations, and neuropsychological testing.
Eligibility Criteria
• Group 1: Patients diagnosed with PD, MSA or PSP.
• Group 2: Patients recently diagnosed with PD broken into two subgroups. Subgroup one will be participants who have not yet begun treatment with medications for PD. Subgroup two will be participants who are currently taking medications to treat PD.
• Group 3: Patients diagnosed with RBD.
Primary Investigator(s)
- David Eidelberg, MD
Contact Information
Last Update
January 18, 2011How did I get to this page?
Persistent Navigation
- Home
- About Us
- Centers of Excellence
- Our Laboratories
- Research Topics
-
Clinical Trials
- Addiction
- Aging
- Allergies
- Arthritis
- Autoimmune Disease
- Blood Disorders
- Cancer
- Children's Health
- Circulation
- Diabetes
- Ear & Hearing
- Eyes
- Gastrointestinal/Hepatitis
- Genetics
- Heart
- HIV
- Infectious Diseases
- Joints
- Kidney
- Lung
- Lupus
- Men's Health
- Mental Health
-
Neurosciences
- Alzheimer's Disease - Memantine Study (06.02.108T)
- Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment, Post-Treatment and at Six Month Follow-up (11-196A)
- Autism Spectrum Disorders - Adult Study (07.04.051)
- Brain and Behavior in Dystonia: A Multicenter Study (03.02.079G)
- Brain and Behavior in Dystonia Study (08-283)
- Brain AVM - Clinical Trial (06.02.063)
- Brain Networks in Parkinson's Disease (04-113T)
- Cannabis - Dopamine Study - (09-002)
- Clinical Correlates of Memory Impairment (03.08.160)
- Dementia - Clinical Trial (08-295)
- Dystonia - Deep Brain Stimulation Study (06-109T)
- Epilepsy
- Epilepsy - Cognitive and Sensorimotor Study (07-125)
- Epilepsy - Genetic Marker and Enzyme Study (07.08.009)
- Epilepsy - Multicenter Study (06.08.058)
- Huntington's Disease - Clinical Trial (09-012)
- Huntington's Disease - Coenzyme Q10 Study (07-124)
- Laparoscopic Experience and Functional Brain Activation (07-106)
- Memory Disorders Study (08-219)
- Metastatic Brain Tumor Study (08-10-24)
- MIF - Spinal Cord Injury Study (09-026)
- Movement Disorders - Functional Correlates Study (08-191)
- Multiple Sclerosis - Diffusion Tensor MRI Correlates of Depression (03.02.084T)
- Neuroendocrine Tumors - Imaging Study (03-117)
- Parkinson's Disease Genetics Database (07-057)
- Parkinson's Disease - Genetic Study (07-058)
- Parkinson's Disease - Molecular Basis for Cognitive Impairment (06-108T)
- Parkinson's Disease - Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel (B09-004)
- Parkinson’s Disease - Early Differential Diagnosis of Parkinsonism with Metabolic Imaging and Pattern Analysis
- Parkinson’s Disease - Efficacy, Safety, and Tolerability of Pioglitazone
- Parkinson’s Disease - Efficacy, Safety and Tolerability of CoganeTM (B10-046)
- Parkinson’s Disease - Efficacy and Safety of Sufinamide (B10-026)
- Parkinson’s Disease - Metabolic Networks and the Cognitive Treatment Response in Parkinson’s Disease
- Parkinson’s Disease - Microvascular Changes in Parkinson’s Disease: Relationship to Levodopa-Induced Dyskinesia
- Parkinson’s Disease - Open-Label Continuation Treatment Study with Levodopa-Carbidopa Intestinal Gel (B10-039)
- Pitch Recognition in Autistic Spectrum Disorders (04-053)
- REM Behavior Disorder and Parkinsonism: Longitudinal PET Study (08-126)
- Schizophrenia-like Effects of Cannibinoids (09-157)
- Swallowing Therapy Study (07-130)
- The General Use of Robots in Stroke Recovery (11-121B)
- Web-delivery Treatment for Substance Abuse (10-016A)
- Radiation Medicine
- Recruitment Registry
- Skin
- Sleep Disorders
- Smoking
- Urinary Tract
- Weight Control
- Women's Health
- Academics
- Resources for Investigators
- Upcoming Events